A Randomized Phase II Study of Multipeptide Vaccination With or Without IL-12, Then Combined With Regulatory T Cell Depletion Using Daclizumab in Patients With Metastatic Melanoma

This randomized phase II trial is studying how well giving vaccine therapy together with or without recombinant interleukin-12 followed by daclizumab works in treating patients with melanoma that has spread to other places in the body. Vaccines made from peptides or antigens may help the body build an effective immune response to kill tumor cells. Recombinant interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating white blood cells to kill melanoma cells. Monoclonal antibodies, such as daclizumab, may decrease the number of regulatory T cells (T cells that suppress the activation of the immmune system) and may lead to a better immune response against melanoma. It is not yet known whether vaccine therapy is more effective with interleukin-12 and daclizumab in treating melanoma.

开始日期2011-02-01

申办/合作机构

National Cancer Institute

100 项与 NA17.A2 Peptide Vaccine(NCI) 相关的临床结果

登录后查看更多信息

100 项与 NA17.A2 Peptide Vaccine(NCI) 相关的转化医学

登录后查看更多信息

100 项与 NA17.A2 Peptide Vaccine(NCI) 相关的专利（医药）

登录后查看更多信息

项与 NA17.A2 Peptide Vaccine(NCI) 相关的文献（医药）

2006-04-01·Cancer Immunology, Immunotherapy2区 · 医学

A new dendritic cell vaccine generated with interleukin-3 and interferon-β induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients

2区 · 医学

Article

作者: Blocklet, Didier ; Coulie, Pierre ; Goldman, Serge ; Velu, Thierry ; Goldman, Michel ; Mortier, Laurent ; Sales, Francois ; Vereecken, Pierre ; Gordower, Laurence ; Laporte, Marianne ; Mazouz, Naima ; Lambermont, Micheline ; Dodoo, Ygierne ; Toungouz, Michel ; Trakatelli, Myrto

Dendritic cells derived from monocytes cultured in the presence of type I interferon were found to induce efficient T cell responses against tumor antigens in vitro. We vaccinated eight stage III or IV melanoma patients with dendritic cells generated with interferon-beta and interleukin-3, activated by poly I: C, and pulsed with the tumor-specific antigen NA17.A2. This dendritic cell vaccine was well-tolerated with only minor and transient flu-like symptoms and inflammatory reactions at the injection sites. In most patients, isotopic imaging documented dendritic cells (DC) migration from the intradermal injection site to the draining lymph nodes. Finally, mixed lymphocyte-peptide culture under limiting dilution conditions followed by tetramer labeling indicated that three out of eight patients mounted a CD8 T cell response against the NA17.A2 antigenic peptide. We conclude that DC generated in type I-IFN represent an interesting alternative to DC generated in IL-4 and GM-CSF for cancer immunotherapy.

100 项与 NA17.A2 Peptide Vaccine(NCI) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性黑色素瘤	临床2期	美国	National Cancer Institute	2011-02-01
皮肤黑色素瘤	临床2期	美国	National Cancer Institute	2011-02-01
转移性黑色素瘤	临床2期	美国	National Cancer Institute	2011-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01307618 (CTgov)	临床2期	皮肤黑色素瘤 \| 复发性黑色素瘤 \| 转移性黑色素瘤	10	Laboratory Biomarker Analysis+NA17.A2 Peptide Vaccine+Recombinant MAGE-3.1 Antigen+MART-1 Antigen (Arm I (Vaccine Therapy))	(網製廠範構窪蓋餘築廠) = 廠觸憲觸選淵夢遞鬱醖願顧膚廠齋艱壓簾築鏇 (願憲醖鹽顧網繭網觸願, 獵糧憲餘範襯蓋觸餘壓 ~ 齋襯夢鏇憲願廠艱壓構) 更多	-	2016-10-24
				Recombinant Interleukin-12+NA17.A2 Peptide Vaccine+Recombinant MAGE-3.1 Antigen (Arm II (Vaccine Therapy, IL-12))	(網製廠範構窪蓋餘築廠) = 憲淵願蓋齋淵醖壓蓋範願顧膚廠齋艱壓簾築鏇 (願憲醖鹽顧網繭網觸願, 簾衊鹹鏇糧鹹網觸繭襯 ~ 鹽蓋襯鑰衊鬱鹽築範選) 更多